文献速递垂体与肾上腺疾病

肢端肥大症治疗的未来发展方向

What is the future of acromegaly therapy?
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

口服生长抑素受体配体已在美国上市,非口服创新剂型如奥曲肽皮下储库剂(CAM2029)可维持生化控制并可能减轻治疗负担;垂体靶向长效制剂及生长激素受体靶向药物亦显示与有效疾病控制一致的药理活性。

要点

  • 口服生长抑素受体配体已在美国上市,长期管理更便利。
  • 奥曲肽皮下储库剂维持生化控制且安全性可接受,或减轻治疗负担。
  • 垂体靶向长效制剂及生长激素受体靶向药物显示有效控制疾病的活性。

核心结论

  • 多种新药进展可能拓宽个体化药物治疗策略,并减轻慢性治疗的实际负担。

主要发现

  • 口服生长抑素受体配体已在美国上市,体现向更便利长期管理的转变。
  • 奥曲肽皮下储库剂(CAM2029)维持生化控制,安全性可接受,并可能减轻治疗负担。
  • 垂体靶向长效制剂(Debio 4126)显示与有效疾病控制一致的药理活性。
  • 生长激素受体靶向药物(ALXN2420、MAR002)显示与显著生化和临床获益一致的活性。

临床怎么用

  • 上述药物可能通过拓宽控制肝脏胰岛素样生长因子I(IGF-I)生成及减弱肝外生长激素信号的选择,满足未被满足的需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acromegaly is a chronic multisystem disorder in which biochemical control remains suboptimal for many patients. Even when control is achieved, treatment burden is often high despite surgery and a spectrum of established safe and effective therapies. In this narrative review of multinational late-stage clinical trials through October 2025, we summarize drug developments that may broaden individualized medical strategies. Oral somatostatin receptor ligands are now available in the United States, underscoring a shift toward more convenient long-term management. In parallel, non-oral innovations continue to advance. Octreotide subcutaneous depot (CAM2029) maintains biochemical control with acceptable safety and may reduce treatment burden. Emerging pituitary-directed therapy with longer application intervals (Debio 4126) also shows pharmacologic activity consistent with effective disease control. Growth hormone (GH) receptor-directed agents (ALXN2420, MAR002) likewise demonstrate activity aligned with considerable biochemical and clinical benefit. Collectively, these agents may address unmet needs by broadening the scope of options to control production of hepatic insulin-like growth factor I (IGF-I) and to attenuate additional extrahepatic GH signaling. They may also help ease the practical burden of chronic therapy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Schilbach K, Strasburger CJ. What is the future of acromegaly therapy? J Clin Endocrinol Metab. 2026. PMID: 41964414. doi:10.1210/clinem/dgag144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。